Baird Financial Group Inc. Invests $276,000 in Takeda Pharmaceutical Co. $TAK

Key Points

• Baird Financial Group Inc. has invested $276,000 in Takeda Pharmaceutical Co., purchasing 18,583 shares during the first quarter.
• Takeda Pharmaceutical reported earnings of $0.52 per share, exceeding analyst expectations of $0.47, but its revenue of $7.45 billion fell short of the projected $7.96 billion.
• Recent analyst ratings show that Takeda's stock has been downgraded to a "strong sell" by Zacks Research, although the average rating remains a "hold."

Baird Financial Group Inc. acquired a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 18,583 shares of the company's stock, valued at approximately $276,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TAK. Soleus Capital Management L.P. grew its position in shares of Takeda Pharmaceutical by 136.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock worth $15,623,000 after buying an additional 680,000 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Takeda Pharmaceutical by 24.6% during the 1st quarter. Federated Hermes Inc. now owns 541,919 shares of the company's stock valued at $8,058,000 after purchasing an additional 106,885 shares in the last quarter. Toronto Dominion Bank bought a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at about $6,760,000. Quantinno Capital Management LP raised its stake in shares of Takeda Pharmaceutical by 33.2% during the 4th quarter. Quantinno Capital Management LP now owns 481,833 shares of the company's stock worth $6,379,000 after purchasing an additional 120,120 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its holdings in shares of Takeda Pharmaceutical by 88.5% during the 1st quarter. Crossmark Global Holdings Inc. now owns 396,833 shares of the company's stock worth $5,901,000 after acquiring an additional 186,349 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Price Performance

NYSE:TAK traded down $0.23 during trading hours on Friday, hitting $15.11. The company's stock had a trading volume of 2,820,524 shares, compared to its average volume of 3,008,668. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The company has a market capitalization of $48.08 billion, a P/E ratio of 50.37 and a beta of 0.22. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.69. The stock has a fifty day simple moving average of $14.81 and a 200-day simple moving average of $14.83.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Takeda Pharmaceutical has a consensus rating of "Hold".

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.